Royalty Pharma (RPRX) Invested Capital (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Invested Capital data on file, last reported at $380.0 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 61.95% year-over-year to $380.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 billion (down 28.53% YoY), and the FY2025 full-year result was $380.0 million, down 61.92% from the prior year.
• Invested Capital was little changed at $380.0 million in Q1 2026, from $380.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $999.4 million in Q2 2025 to a low of $116.0 million in Q2 2022.
• A 5-year average of $719.7 million and a median of $996.9 million in 2024 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital soared 824.19% in 2022 and tumbled 61.95% in 2026, its largest moves.
• Tracing RPRX's Invested Capital over 5 years: stood at $997.5 million in 2022, then increased by 0.19% to $999.4 million in 2023, then slipped by 0.16% to $997.8 million in 2024, then slumped by 61.92% to $380.0 million in 2025, then changed by 0.0% to $380.0 million in 2026.
• Business Quant data shows RPRX's Invested Capital at $380.0 million in Q1 2026, $380.0 million in Q4 2025, and $380.0 million in Q3 2025.